logo-loader
viewReNeuron Group PLC

ReNeuron focus on new clinical trials

The cell therapy specialist ReNeuron Group Plc (LON:RENE) is gearing up for a busy 18 months with read-outs from two clinical trials expected during 2019/20. ReNeuron CFO Michael Hunt tells Proactive London that there's sufficient cash in the bank for those two key studies, both of which are in the US. Talk here too of ongoing business development programmes for ReNeuron wityh Hunt also touching on last week's interims, which he characterises as 'business as usual'.
Patient screening and enrolment have commenced for ReNeuron's most advanced programme, a CTX therapy for stroke, which is entering phase IIb clinical trials, with top-line data from the US study expected in early 2020.

Quick facts: ReNeuron Group PLC

Price: 138 GBX

LSE:RENE
Market: LSE
Market Cap: £43.93 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 posts early losses sparked by rising US coronavirus...

Headlines from the Proactive UK newsroom. FTSE100 posted early losses sparked by rising US coronavirus infections and China’s trade row with the US. The blue-chip index shed 10 points to 6,112. Royal Mail PLC (LON:RMG) is to axe 2,000 jobs or more than 20% of its managerial staff as part...

1 week, 5 days ago

2 min read